These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 27440268)

  • 1. Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in Neuroblastoma.
    Chicard M; Boyault S; Colmet Daage L; Richer W; Gentien D; Pierron G; Lapouble E; Bellini A; Clement N; Iacono I; Bréjon S; Carrere M; Reyes C; Hocking T; Bernard V; Peuchmaur M; Corradini N; Faure-Conter C; Coze C; Plantaz D; Defachelles AS; Thebaud E; Gambart M; Millot F; Valteau-Couanet D; Michon J; Puisieux A; Delattre O; Combaret V; Schleiermacher G
    Clin Cancer Res; 2016 Nov; 22(22):5564-5573. PubMed ID: 27440268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shallow Whole Genome Sequencing on Circulating Cell-Free DNA Allows Reliable Noninvasive Copy-Number Profiling in Neuroblastoma Patients.
    Van Roy N; Van Der Linden M; Menten B; Dheedene A; Vandeputte C; Van Dorpe J; Laureys G; Renard M; Sante T; Lammens T; De Wilde B; Speleman F; De Preter K
    Clin Cancer Res; 2017 Oct; 23(20):6305-6314. PubMed ID: 28710315
    [No Abstract]   [Full Text] [Related]  

  • 3. Radiogenomics of neuroblastomas: Relationships between imaging phenotypes, tumor genomic profile and survival.
    Brisse HJ; Blanc T; Schleiermacher G; Mosseri V; Philippe-Chomette P; Janoueix-Lerosey I; Pierron G; Lapouble E; Peuchmaur M; Fréneaux P; Galmiche L; Algret N; Peycelon M; Michon J; Delattre O; Sarnacki S
    PLoS One; 2017; 12(9):e0185190. PubMed ID: 28945781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation of copy number aberrations: Comparison of exome sequencing data with SNP microarrays identifies homozygous deletions of 19q13.2 and CIC in neuroblastoma.
    Fransson S; Östensson M; Djos A; Javanmardi N; Kogner P; Martinsson T
    Int J Oncol; 2016 Mar; 48(3):1103-16. PubMed ID: 26794043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma.
    Chen QR; Bilke S; Wei JS; Whiteford CC; Cenacchi N; Krasnoselsky AL; Greer BT; Son CG; Westermann F; Berthold F; Schwab M; Catchpoole D; Khan J
    BMC Genomics; 2004 Sep; 5():70. PubMed ID: 15380028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic implication.
    Wolf M; Korja M; Karhu R; Edgren H; Kilpinen S; Ojala K; Mousses S; Kallioniemi A; Haapasalo H
    BMC Cancer; 2010 May; 10():181. PubMed ID: 20444257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age dependence of tumor genetics in unfavorable neuroblastoma: arrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation.
    Cetinkaya C; Martinsson T; Sandgren J; Träger C; Kogner P; Dumanski J; Díaz de Ståhl T; Hedborg F
    BMC Cancer; 2013 May; 13():231. PubMed ID: 23656755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of genomic alterations in neuroblastoma by multiplex ligation-dependent probe amplification and array comparative genomic hybridization: a comparison of results.
    Combaret V; Iacono I; Bréjon S; Schleiermacher G; Pierron G; Couturier J; Bergeron C; Blay JY
    Cancer Genet; 2012 Dec; 205(12):657-64. PubMed ID: 23265803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.
    Gupta S; Hovelson DH; Kemeny G; Halabi S; Foo WC; Anand M; Somarelli JA; Tomlins SA; Antonarakis ES; Luo J; Dittamore RV; George DJ; Rothwell C; Nanus DM; Armstrong AJ; Gregory SG
    Genes Chromosomes Cancer; 2020 Apr; 59(4):225-239. PubMed ID: 31705765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of whole chromosome X predicts prognosis of neuroblastoma patients with numerical genomic profile.
    Parodi S; Pistorio A; Erminio G; Ognibene M; Morini M; Garaventa A; Gigliotti AR; Haupt R; Frassoni F; Pezzolo A
    Pediatr Blood Cancer; 2019 May; 66(5):e27635. PubMed ID: 30688024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic Profiles of Neuroblastoma Associated With Opsoclonus Myoclonus Syndrome.
    Hero B; Clement N; Øra I; Pierron G; Lapouble E; Theissen J; Pasqualini C; Valteau-Couanet D; Plantaz D; Michon J; Delattre O; Tardieu M; Schleiermacher G
    J Pediatr Hematol Oncol; 2018 Mar; 40(2):93-98. PubMed ID: 29135842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ArrayCGH-based classification of neuroblastoma into genomic subgroups.
    Michels E; Vandesompele J; De Preter K; Hoebeeck J; Vermeulen J; Schramm A; Molenaar JJ; Menten B; Marques B; Stallings RL; Combaret V; Devalck C; De Paepe A; Versteeg R; Eggert A; Laureys G; Van Roy N; Speleman F
    Genes Chromosomes Cancer; 2007 Dec; 46(12):1098-108. PubMed ID: 17823929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accumulation of segmental alterations determines progression in neuroblastoma.
    Schleiermacher G; Janoueix-Lerosey I; Ribeiro A; Klijanienko J; Couturier J; Pierron G; Mosseri V; Valent A; Auger N; Plantaz D; Rubie H; Valteau-Couanet D; Bourdeaut F; Combaret V; Bergeron C; Michon J; Delattre O
    J Clin Oncol; 2010 Jul; 28(19):3122-30. PubMed ID: 20516441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome.
    Spitz R; Oberthuer A; Zapatka M; Brors B; Hero B; Ernestus K; Oestreich J; Fischer M; Simon T; Berthold F
    Genes Chromosomes Cancer; 2006 Dec; 45(12):1130-42. PubMed ID: 16958102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromosomal localization of DNA amplifications in neuroblastoma tumors using cDNA microarray comparative genomic hybridization.
    Beheshti B; Braude I; Marrano P; Thorner P; Zielenska M; Squire JA
    Neoplasia; 2003; 5(1):53-62. PubMed ID: 12659670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
    Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
    Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
    [No Abstract]   [Full Text] [Related]  

  • 17. The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.
    Bogen D; Brunner C; Walder D; Ziegler A; Abbasi R; Ladenstein RL; Noguera R; Martinsson T; Amann G; Schilling FH; Ussowicz M; Benesch M; Ambros PF; Ambros IM
    Int J Cancer; 2016 Jul; 139(1):153-63. PubMed ID: 26910568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overall genomic pattern is a predictor of outcome in neuroblastoma.
    Janoueix-Lerosey I; Schleiermacher G; Michels E; Mosseri V; Ribeiro A; Lequin D; Vermeulen J; Couturier J; Peuchmaur M; Valent A; Plantaz D; Rubie H; Valteau-Couanet D; Thomas C; Combaret V; Rousseau R; Eggert A; Michon J; Speleman F; Delattre O
    J Clin Oncol; 2009 Mar; 27(7):1026-33. PubMed ID: 19171713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence.
    Pinto N; Mayfield JR; Raca G; Applebaum MA; Chlenski A; Sukhanova M; Bagatell R; Irwin MS; Little A; Rawwas J; Gosiengfiao Y; Delattre O; Janoueix-Lerosey I; Lapouble E; Schleiermacher G; Cohn SL
    Pediatr Blood Cancer; 2016 Jun; 63(6):1019-23. PubMed ID: 26864375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA.
    Clark TA; Chung JH; Kennedy M; Hughes JD; Chennagiri N; Lieber DS; Fendler B; Young L; Zhao M; Coyne M; Breese V; Young G; Donahue A; Pavlick D; Tsiros A; Brennan T; Zhong S; Mughal T; Bailey M; He J; Roels S; Frampton GM; Spoerke JM; Gendreau S; Lackner M; Schleifman E; Peters E; Ross JS; Ali SM; Miller VA; Gregg JP; Stephens PJ; Welsh A; Otto GA; Lipson D
    J Mol Diagn; 2018 Sep; 20(5):686-702. PubMed ID: 29936259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.